Company Profile
BioSyent acquires or licenses, develops, and sells pharmaceutical and other healthcare products in Canada and globally. Its products include FeraMAX Pd Therapeutic 150 for the treatment of iron deficiency anemia.
Its portfolio also includes FeraMAX Pd Maintenance 45, a chewable supplement for the prevention of iron deficiency anemia, and FeraMAX Pd Powder 15, a powder form product used for preventing iron deficiency and iron deficiency anemia.
It offers Tibella, a hormone replacement therapy consisting of tibolone. Its portfolio also includes Inofolic, a natural health product to address polycystic ovarian syndrome symptoms, RepaGyn, a vaginal suppository for the healing of the vaginal mucosa For the treatment of vaginal dryness caused by aging, menopause, stress, and chemotherapy, and Gelclair, a gel formulated to aid the pain or oral mucositis
Cathejell, a lubricant with anesthetic with the indication of lubricating and opening the urethra before the insertion of the catheter Proktis-M, a rectal suppository for the healing of the anus and rectum. Distribution is handled through wholesalers and retail pharmacy chains.
BioSyent Inc. was formerly known as Hedley Technologies Inc. and changed its name to BioSyent Inc. in June 2006. Incorporated in 2006, the company is headquartered in Mississauga, Canada.